Formosa Pharmaceuticals, founded in 2010, is a late-preclinical and early-clinical stage biopharmaceutical company with focus in the indications of ophthalmology, oncology, and anti-infectives.
In August, 2017, Formosa Pharmaceuticals acquired Activus Pharmaceuticals (Funabashi, Japan), which afforded Formosa Pharmaceuticals a proprietary nanoparticle technology platform (APNT), and two late-stage preclinical assets in ophtha...
Formosa Pharmaceuticals, founded in 2010, is a late-preclinical and early-clinical stage biopharmaceutical company with focus in the indications of ophthalmology, oncology, and anti-infectives.
In August, 2017, Formosa Pharmaceuticals acquired Activus Pharmaceuticals (Funabashi, Japan), which afforded Formosa Pharmaceuticals a proprietary nanoparticle technology platform (APNT), and two late-stage preclinical assets in ophthalmology. Of these ophthalmology candidates, APP13007 has just begun Phase 3 clinical trials in the United States for inflammation and pain after ocular surgery.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.